

GAVI/14/415/dlc/ac

The Minister of Public Health and Population
Ministry of Public Health and Population
P.O. Box 299
Sana'a
Yemen

23 September 2014

Dear Minister,

**Management Letter: *Request for 2015 Renewal of GAVI support for
Renewal of Vaccine Support***

This management letter accompanies the Decision Letter about Yemen 's request for renewal for New Vaccines Support (NVS) for Rota, PCV and Pentavalent vaccine, which was reviewed by the GAVI Alliance High Level Review Panel (HLRP) on 23-25 July 2014.

The HLRP replaces the monitoring Independent Review Committee in making recommendations to GAVI's Chief Executive Officer on the renewal of GAVI support for existing grants. This change is part of GAVI's new grant application, monitoring and review system, which is designed to lower transaction costs for countries, ensure closer coordination with countries' planning cycles, better align NVS and HSS support, and improve fiduciary oversight. The Review Panel, composed of Alliance partners, is designed to increase the accountability of the Alliance, and to streamline the review processes. The Panel will meet several times a year to enable alignment with countries' budgetary and planning cycles.

The internal appraisal conducted by GAVI has noted the following recommended areas for action. We encourage you to work to ensure these points are adequately addressed. We request that you review the table below and provide us feedback on the suggested actions and timeframe to address the comments. I would be happy to have a discussion on these comments at your earliest convenience should this be required:

Comment	Suggested Action	Timeframe
The country to take action to finalize and implement the 2014 EVM improvement plan recommendations.		
PCV and Rota targets may need to be adjusted downwards based on		

stock analysis		
The country to ensure robust reporting systems and data quality		
The country to develop mechanism for gathering gender desegregated data		
The country to ensure more robust involvement of CSOs at all levels		
HSS component to ensure sustainable involvement of CHV and their quality training with effective supervision		
<p>Regarding Financial management:</p> <p>Country to take appropriate and remedial action and inform GAVI on all of the following items for ISS, HSS, and NVS:</p> <ul style="list-style-type: none"> • 2011 detailed Expenditure report for each cash program • bank statement with opening and closing balances for 2012 • For HSS -to explain discrepancy of \$ 90,943 <p>Maintain Books of accounts instead of use of spread sheets; Keep proper monthly payroll sheets not;</p> <p>Provide Supporting Documents for Receipts of funds which were not available to auditors;</p> <p>Clear with 3rd party proper documentation, the amount of \$ 47,422 advanced under ISS and inform the secretariat;</p> <p>Provide other bank statements for grant funds. Only one bank statement has been provided but opening and closing balances do not reconcile with any of the programs;</p> <p>Provide and implement an action plan to remedy the weaknesses in accounting and controls over advances.</p> <p>Provide banks Statements for 2013 showing balances at 1/1/2013 and</p>		

31/12/2013.		
-------------	--	--

The Decision Letter and related appendices are attached to this message. Please do not hesitate to contact me at acronin@gavi.org if you have any questions or concerns. I would be happy to set up a teleconference to discuss this further should this be required.

Yours sincerely,



Anne Cronin
Senior Country Manager

Attachments: Yemen's Internal Appraisal

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
The World Bank

Yemen VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Yemen			
2. Grant Number: 1115-YEM-12c-X			
3. Date of Decision Letter: 23/09/2014			
4. Date of the Partnership Framework Agreement: 08/2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2010 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2010-2014	2015	Total ²
Programme Budget (US\$)	US\$68,201,358 ³	US\$8,901,500	US\$77,102,858
10. Vaccine Introduction Grant: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴																
Type of supplies to be purchased with GAVI funds in each year	2010-2014	2015														
Number of Pneumococcal vaccines doses		1,609,200														
Number of AD syringes		1,640,600														
Number of re-constitution syringes																
Number of safety boxes		18,050														
Annual Amounts (US\$)	US\$68,201,358 ⁵	US\$8,901,500														
12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.																
13. Self-procurement: Not applicable.																
<p>14. Co-financing obligations: Reference code: 1115-YEM-12c-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>145,800</td> </tr> <tr> <td>Number of AD syringes</td> <td>148,000</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>1,650</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$489,206</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$526,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	145,800	Number of AD syringes	148,000	Number of re-constitution syringes		Number of safety boxes	1,650	Value of vaccine doses (US\$)	US\$489,206	Total Co-Financing Payments (US\$) (including freight)	US\$526,500
Type of supplies to be purchased with Country funds in each year	2015															
Number of vaccine doses	145,800															
Number of AD syringes	148,000															
Number of re-constitution syringes																
Number of safety boxes	1,650															
Value of vaccine doses (US\$)	US\$489,206															
Total Co-Financing Payments (US\$) (including freight)	US\$526,500															
15. Operational support for campaigns: Not applicable																

⁴ This is the amount that GAVI has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional documents to be delivered for future disbursements: Not applicable	
Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the year 2014
<p>17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: <i>Not applicable</i> <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i></p>	
<p>18. Other conditions: Not applicable.</p>	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
 Managing Director, Country Programmes
 23 September 2014

Yemen VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Yemen			
2. Grant Number: 0715-YEM-04a-X			
3. Date of Decision Letter: 23/09/2014			
4. Date of the Partnership Framework Agreement: 08/2014			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme Duration⁶: 2005 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2005-2014	2015	Total ⁷
Programme Budget (US\$)	US\$62,074,702 ⁸	US\$2,754,500	US\$64,829,202
10. Vaccine Introduction Grant: Not applicable			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹

Type of supplies to be purchased with GAVI funds in each year	2005-2014	2015
Number of Pentavalent vaccines doses		1,333,000
Number of AD syringes		1,367,300
Number of re-constitution syringes		
Number of safety boxes		15,050
Annual Amounts (US\$)	US\$62,074,702 ¹⁰	US\$2,754,500

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 0715-YEM-04a-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	545,500
Number of AD syringes	559,500
Number of re-constitution syringes	
Number of safety boxes	6,175
Value of vaccine doses (US\$)	US\$1,063,060
Total Co-Financing Payments (US\$) (including freight)	US\$1,127,500

15. Operational support for campaigns: Not applicable

⁹ This is the amount that GAVI has approved.

¹⁰ This is the consolidated amount for all previously approved years.

16. Additional documents to be delivered for future disbursements: Not applicable	
Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the year 2014
17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: Not applicable <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i>	
18. Other conditions: Not applicable	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
 Managing Director, Country Programmes
 23 September 2014

Yemen VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Yemen			
2. Grant Number: 1215-YEM-13b-X			
3. Date of Decision Letter: 23/09/2014			
4. Date of the Partnership Framework Agreement:08/2014			
5. Programme Title: NVS, Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme Duration¹¹: 2012 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2012-2014	2015	Total ¹²
Programme Budget (US\$)	US\$11,704,323 ¹³	US\$3,151,500	US\$14,855,823
10. Vaccine Introduction Grant: Not applicable			

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

¹³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):¹⁴		
Type of supplies to be purchased with GAVI funds in each year	2012-2014	2015
Number of Rotavirus vaccines doses		1,188,000
Number of AD syringes		
Number of re-constitution syringes		
Number of safety boxes		
Annual Amounts (US\$)	US\$11,704,323 ¹⁵	US\$3,151,500

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1215-YEM-13b-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate.
The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	151,500
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$386,701
Total Co-Financing Payments (US\$) (including freight)	US\$402,000


15. Operational support for campaigns: Not applicable

¹⁴ This is the amount that GAVI has approved.

¹⁵ This is the consolidated amount for all previously approved years.

16. Additional documents to be delivered for future disbursements: Not applicable	
Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat in the context of GAMR Joint Appraisal process on support for the year 2014
17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: Not applicable <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i>	
18. Other conditions: Not applicable	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
 Managing Director, Country Programmes
 23 September 2014